Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori

被引:13
|
作者
Zhang, Lingyun [1 ]
Lan, Yu [1 ]
Wang, Qi [1 ]
Zhang, Yuexia [1 ]
Si, Xiaobei [1 ]
机构
[1] Beijing Jishuitan Hosp, Dept Gastroenterol, 68 Hui Nan Rd, Beijing 100096, Peoples R China
关键词
INFECTION; RESISTANCE;
D O I
10.1155/2019/9251879
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aim. To evaluate the eradication rate, safety, and compliance of minocycline-containing bismuth quadruple regimens in patients with an untreated Helicobacter pylori (H. pylori) infection. Methods. A total of 360 patients with an untreated H. pylori infection were enrolled in this study between June 2017 and October 2018. Patients were randomly divided into a minocycline/amoxicillin (RMAB) group, a minocycline/metronidazole (RMMB) group, or an amoxicillin/clarithromycin (RACB) group, and all groups received a combined treatment approach with rabeprazole and bismuth to create a quadruple regimen for 14 days. A 3 to 5-day follow-up was adopted to evaluate the safety and compliance of medications after medicine administration. C-13-urea breath test was performed to confirm the eradication of H. pylori 4-12 weeks after therapy. Results. No significant differences were observed at baseline data among the three groups (p>0.05). Based on the intent-to-treat analysis, the eradication rates of the RMAB group, RMMB group, and RACB control group were 85.7% (102/119), 77.1% (91/118), and 71.7% (86/120), respectively, with significant difference (chi 2=7.015, p=0.030). According to per protocol analysis, the eradication rates of RMAB group, RMMB group, and RACB group were 89.5% (102/114), 84.3% (91/108), and 76.8% (86/112), respectively, with statistically significant differences (chi 2=6.673, p=0.036). The eradication rates of the RMAB group and RACB group were significantly different (p<0.05). The overall incidences of adverse events in the three groups were 30.0%, 37.5%, and 40.0%, respectively (p>0.05). Nausea, epigastric discomfort, and dizziness were more obvious in patients in the RMMB group compared to the other two groups (p<0.05). Moreover, two patients discontinued due to severe dizziness and nausea in the RMMB group. A taste disorder was more prominent in patients in the RACB group compared to patients in the other two groups (p<0.05), and one patient discontinued because of the bitterness in the mouth. Soon after discontinuation of the medicine, all adverse events disappeared. Conclusion. The bismuth quadruple regimen using minocycline/amoxicillin showed a better eradication effect with fewer side effects in patients with untreated H. pylori infections. The bismuth quadruple regimen with minocycline/metronidazole had a good eradication effect with more obvious side effects and might be recommended to patients with penicillin allergy.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori (vol 2019, 9251879, 2019)
    Zhang, Lingyun
    Lan, Yu
    Wang, Qi
    Zhang, Yuexia
    Si, Xiaobei
    [J]. GASTROENTEROLOGY RESEARCH AND PRACTICE, 2021, 2021
  • [2] Comparison of bismuth-containing quadruple and concomitant therapies as a first-line treatment option for Helicobacter pylori
    Uygun, Ahmet
    Kadayifci, Abdurrahman
    Polat, Zulfikar
    Kantarcioglu, Murat
    Kilciler, Guldem
    Baser, Omer
    Ozcan, Ayhan
    Emer, Ozdes
    [J]. TURKISH JOURNAL OF GASTROENTEROLOGY, 2012, 23 (01): : 8 - 13
  • [3] The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori
    Uygun, A.
    Kadayifci, A.
    Safali, M.
    Ilgan, S.
    Bagci, S.
    [J]. HELICOBACTER, 2007, 12 (04) : 430 - 430
  • [4] The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori
    Uygun, Ahmet
    Kadayifci, Abdurrahman
    Safali, Mukerrem
    Ilgan, Seyfettin
    Bagci, Sait
    [J]. JOURNAL OF DIGESTIVE DISEASES, 2007, 8 (04) : 211 - 215
  • [5] Quadruple therapy with moxifloxacin and bismuth for first-line treatment of Helicobacter pylori
    Ciccaglione, Antonio Francesco
    Cellini, Luigina
    Grossi, Laurino
    Marzio, Leonardo
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (32) : 4386 - 4390
  • [6] Modified quadruple therapy or bismuth-containing quadruple therapy in the first-line treatment of Helicobacter pylori in Turkey
    Yozgat, Ahmet
    Kasapoglu, Benan
    Demirci, Selim
    Sokmen, Fevzi Coskun
    [J]. REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2021, 113 (07) : 490 - 493
  • [7] Rabeprazole, Minocycline, Amoxicillin, and Bismuth as First-Line and Second-Line Regimens for Helicobacter pylori Eradication
    Song, Zhiqiang
    Suo, Baojun
    Zhang, Lingyun
    Zhou, Liya
    [J]. HELICOBACTER, 2016, 21 (06) : 462 - 470
  • [8] Esomeprazole, minocycline, metronidazole and bismuth as first-line and second-line regimens for Helicobacter pylori eradication
    Song, Zhi Qiang
    Zhou, Li Ya
    [J]. JOURNAL OF DIGESTIVE DISEASES, 2016, 17 (04) : 260 - 267
  • [9] The Efficacy and Safety of Minocycline-Containing Quadruple Therapies Against Helicobacter pylori Infection: A Retrospective Cohort Study
    Si, Xiao-Bei
    Zhang, Ling-Yun
    Yang, Shuo
    Chen, Xiao-Lu
    Shi, Yan-Yan
    Lan, Yu
    Ding, Shi-Gang
    [J]. INFECTION AND DRUG RESISTANCE, 2024, 17 : 2513 - 2529
  • [10] Optimization of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Real-World Evidence Study
    Huang, Yu
    Qiu, Shuhan
    Guo, Yixian
    Chen, Jinnan
    Li, Meixuan
    Ding, Zhaohui
    Zhang, Wei
    Liang, Xiao
    Lu, Hong
    [J]. HELICOBACTER, 2024, 29 (05)